Financing ·
Alaunos Therapeutics raises $915,400 in registered direct offering of common stock and pre-funded warrants
TCRTAlaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. completed a registered direct offering of common stock on September 21, 2026, raising approximately $915,400 in net proceeds after deducting placement agent fees and expenses. The company issued 380,469 shares at $1.46 per share and 386,654 pre-funded warrants exercisable at $0.001 per share to accredited investors, with gross proceeds totaling approximately $1,120,000. Dawson James Securities, Inc. served as the exclusive placement agent, receiving an 8% cash fee. Proceeds are designated for general corporate purposes and working capital. Officers and directors entered into 15-day lock-up agreements restricting transfers of their holdings. Alaunos Therapeutics is a biotechnology company focused on developing novel therapeutics for obesity and metabolic disorders.